Our Take
This is a career pivot story dressed as science—Cernak's work is real, but the novelty claim (AlphaFold + robotics) is standard pharma workflow applied to a new patient population.
Why it matters
As species face extinction and conservation tools remain chemically crude, chemists who can think across human and animal biology are rare. Cernak's framing of 'conservation chemistry' signals a gap between biotech capability and conservation practice.
Do this week
Conservation directors: audit your current pharmacological toolkit for animal treatments—if you're using human-formulated drugs or blunt-force chemicals (like itraconazole on frogs), map the cost and timeline to partner with a precision-chemistry lab.
A Big Pharma chemist moves to treating wildlife with precision medicine
Tim Cernak spent nearly two decades at Merck designing precision therapies for cancer, HIV, and diabetes in humans. In 2018, he shifted focus. Now an associate professor at the University of Michigan, he applies the same design discipline to animals: a Gila monster with a parasite, bald eagles with avian flu, loggerhead sea turtles with contagious tumors, and even hemlock trees under attack from invasive insects.
The problem he identified is straightforward. When animals fall ill, veterinarians often treat them with pharmaceuticals formulated for human patients. These drugs are indiscriminate—like old-generation cancer therapies that kill healthy cells along with diseased ones. The standard antifungal for frogs with skin infections, itraconazole, is often lethal to the amphibians it's meant to save. Cernak's vision: "the patient was always meant to be a frog in the first place, from the beginning to the end."
The conservation chemistry gap is real, but this is not new method
Cernak's toolkit is familiar to any drug-design team: Google DeepMind's AlphaFold to visualize mutant protein structures on screen (rather than growing them on plates), followed by rapid iterative synthesis. With robotic systems in the lab, he can run through 1,500 reaction candidates per day. This workflow is standard in pharmaceutical R&D.
What is notable is the patient population. Conservation has historically relied on pesticides and off-the-shelf pharmaceuticals—tools Cernak describes as "not cutting-edge." DDT decimated bald eagle populations in the 1960s. A painkiller given to cattle killed millions of vultures in India in the 1990s. Yet chemists with the expertise to design precision therapies for animals remain absent from conservation. The capability exists. The application is new.
Cernak calls this field "conservation chemistry," aware that the term carries historical weight and risk. He acknowledges the dangers but argues that excluding pharmaceutical chemists from conservation is a missed opportunity in the midst of mass extinction.
Who should act on this
This story is not a call for every conservation program to hire a precision chemist. It is a signal that when standard animal treatments fail or carry unacceptable harm, the scientific infrastructure to design alternatives exists—and is underutilized. Practitioners working with endangered species or conservation veterinarians treating endemic wildlife disease should map their current pharmaceutical dependencies and identify which treatments could benefit from species-specific design.